SCHEMBL4126440

SCHEMBL4126440

CN(NC(=O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12)c1cccc(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.37
JAK1 P23458 2/20 0.37
KMT2A Q03164 1/20 0.36
IRAK4 Q9NWZ3 6/20 0.36
GPBAR1 Q8TDU6 1/20 0.35
F10 P00742 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
NPC1 O15118 1/20 0.35
NLRP3 Q96P20 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
LRRK2 Q5S007 1/20 0.35
KDR P35968 1/20 0.35
CYP3A4 P08684 1/20 0.35
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31061014 1.00 JAK2 (0.37) JAK2JAK1KMT2AIRAK4GPBAR1
SCHEMBL4108655 0.93 RAB9A (0.37) JAK2JAK1KMT2AIRAK4GPBAR1
SCHEMBL4118485 0.87 RAB9A (0.40) JAK2JAK1IRAK4F10RAB9A
SCHEMBL4114240 0.87 RAB9A (0.37) JAK2JAK1RAB9ASMN1; SMN2MAPT
SCHEMBL4118760 0.87 LMNA (0.34) KMT2AGPBAR1RAB9ASMN1; SMN2MAPT
SCHEMBL4130225 0.87 OXTR (0.38) KMT2AGPBAR1RAB9ASMN1; SMN2MAPT
SCHEMBL4121225 0.85 JAK2 (0.36) JAK2JAK1IRAK4RAB9ASMN1; SMN2
SCHEMBL4108662 0.84 LMNA (0.35) RAB9ASMN1; SMN2MAPTNPC1KDR
SCHEMBL4129143 0.80 RAB9A (0.42) KMT2AIRAK4F10RAB9ASMN1; SMN2
SCHEMBL4121624 0.80 PDE4A (0.45) RAB9ASMN1; SMN2MAPTNPC1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US claimed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US claimed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP claimed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO claimed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD JAK2 59/4885JAK1 116/4885KMT2A 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.